Identifying PCNSL as being of the MCD subtype, either by identifying a MYD88L265P mutation or a variant of CD79B, may have potential therapeutic implications, as tumours of this subtype are sensitive to treatment using BTK inhibitors. The gene discussed is CD79B; the disease is primary central nervous system lymphoma.